134 related articles for article (PubMed ID: 31480929)
1. Changing Medicare's Protected Classes: History, Mistrust, and Budgets in the Prescription Drug Market.
Frank RG
Psychiatr Serv; 2019 Oct; 70(10):858-859. PubMed ID: 31480929
[No Abstract] [Full Text] [Related]
2. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
3. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
Socal MP; Bai G; Anderson GF
JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
[TBL] [Abstract][Full Text] [Related]
4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
5. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
[TBL] [Abstract][Full Text] [Related]
6. Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D.
Duggan M; Healy P; Morton FS
J Econ Perspect; 2008; 22(4):69-92. PubMed ID: 19768843
[No Abstract] [Full Text] [Related]
7. Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors.
Hernandez I; Gabriel N; Kaltenboeck A; Boccuti C; Hansen RN; Sullivan SD
JAMA; 2023 Dec; 330(24):2390-2392. PubMed ID: 38051277
[TBL] [Abstract][Full Text] [Related]
8. PDPs see increases in cost-sharing amounts.
Manag Care; 2009 Aug; 18(8):55. PubMed ID: 19731513
[No Abstract] [Full Text] [Related]
9. How do seniors respond to 100% cost-sharing for prescription drugs? Quality of the evidence underlying opinions about the Medicare Part D coverage gap.
Fairman KA; Curtiss FR
J Manag Care Pharm; 2011 Jun; 17(5):382-92. PubMed ID: 21657807
[TBL] [Abstract][Full Text] [Related]
10. Drug cost-sharing amounts stable 2010-2011.
Manag Care; 2012 Jan; 21(1):59. PubMed ID: 22334940
[No Abstract] [Full Text] [Related]
11. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
12. The Case for Restructuring the Medicare Prescription Drug Benefit.
Frakt A; Miller M
Health Serv Res; 2018 Dec; 53(6):4132-4137. PubMed ID: 30069872
[No Abstract] [Full Text] [Related]
13. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
Duggan M; Morton FS
Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
[No Abstract] [Full Text] [Related]
14. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
[TBL] [Abstract][Full Text] [Related]
16. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
Padula WV; Ballreich J; Anderson GF
Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
[TBL] [Abstract][Full Text] [Related]
17. Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis.
Hohmann N; Hansen R; Garza KB; Harris I; Kiptanui Z; Qian J
Value Health; 2018 Oct; 21(10):1186-1191. PubMed ID: 30314619
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for Lowering Prescription Drug Spending in Public Programs.
Jazowski SA; Dusetzina SB
Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
[No Abstract] [Full Text] [Related]
19. The impact of the Medicare Part D prescription benefit on generic drug use.
Zhang JX; Yin W; Sun SX; Alexander GC
J Gen Intern Med; 2008 Oct; 23(10):1673-8. PubMed ID: 18661190
[TBL] [Abstract][Full Text] [Related]
20. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
